Two triple quads achieve a new global standard in mass spectrometry - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Two triple quads achieve a new global standard in mass spectrometry

Two triple quadrupole mass spectrometers LCMS-8040 and GCMS-TQ8030 complete Shimadzu’s UFMS series consisting of seven powerful systems. The UFMS product family provides higher sensitivity, greater excellence in data quality, increased analytical throughput and a wider range of applications.

The LCMS-8040 expand the analytical range of Shimadzu's LC-MS/MS lineup while the GCMS-TQ8030 achieves new levels of high-speed and highly-sensitive analysis in GCMS analysis.

GCMS-TQ8030 - ultra-fast analysis meets sensitivity and accuracy
The GCMS-TQ8030 achieves the highest sensitivity in its class for multiple reaction monitoring (MRM) measurements based on UFsweeper® technology.  Superior mass spectra and sensitivity at high scan speeds of up to 20,000 masses/sec is achieved using Advanced Scanning Speed Protocol (ASSP™).

The GCMS-TQ8030’s ecology mode reduces carbon dioxide emissions through a reduction of power consumption in analysis standby mode of 36 percent while also decreasing the consumption of carrier gas.

LCMS-8040 - Expanded range of ultra-fast, high-sensitivity applications
The system combines newly improved ion optics and collision cell technology with proprietary ultrafast technologies. This significantly expands the application range and ensures high-sensitivity, high-throughput analysis at lower levels of detection. A five-fold increase in sensitivity (reserpine, S/N ratio) has been achieved when compared with the LCMS-8030 model.

The LCMS-8040 is the world’s fastest LCMS/MS tandem mass spectrometer and provides multiple reaction monitoring (MRM) transition speeds of up to 555 MRMs per second. This is based on UFsweeper® II collision cell technology that maintains sensitivity and suppresses cross-talk, even for high-speed or simultaneous multi-component analyses.

 

For more information please visit www.shimadzu.eu.

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
26%
Attracting a skilled workforce
29%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
31%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
FindPharma Custom Search

Click here